Eli Lilly Phase 2 Data Showed Eloratzp Delivered Weight Loss Of Up To Average Of 54.1 Lbs (23.3%) At 48 Weeks In Adults With Obesity, Type 2 Diabetes

By Reuters News

- Eli Lilly and Company LLY.N:

  • ELI LILLY: PHASE 2 DATA SHOWED ELORATZP DELIVERED WEIGHT LOSS OF UP TO AVERAGE OF 54.1 LBS (23.3%) AT 48 WEEKS IN ADULTS WITH OBESITY, TYPE 2 DIABETES

  • ELI LILLY: ELORATZP LOWERED A1C BY UP TO AVERAGE OF 2.9%, WITH UP TO 77% OF PARTICIPANTS ACHIEVING NORMAL BLOOD SUGAR LEVELS

  • ELI LILLY: PHASE 3 SURMOUNT-ADOLESCENTS SHOWED ZEPBOUND REDUCED BMI BY AVERAGE OF 21.4% IN ADOLESCENTS AGED 12 TO <18 YEARS WITH OBESITY

Source text: [ID:]

Further company coverage: LLY.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk